Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Public Meeting of South Texas Nuclear Project Environmental Impact Statement scheduled for May 6th March 19, 2010